Home > Cardiology > AHA 2020 > Stroke > Ticagrelor/aspirin reduces stroke risk in patients with ipsilateral cervicocranial plaque

Ticagrelor/aspirin reduces stroke risk in patients with ipsilateral cervicocranial plaque

Presented By
Prof. Pierre Amarenco, Paris University, France
Conference
AHA 2020
Trial
THALES

In patients with a transient ischaemic attack (TIA) or a minor acute ischaemic stroke with ipsilateral stenosis of the cervicocranial vasculature, the P2Y12 inhibitor ticagrelor added to aspirin reduced the risk of recurrent stroke within 30 days by 27% in the THALES trial [1].

Among patients with a TIA or minor ischaemic strokes, ipsilateral atherosclerotic stenosis of cervicocranial vasculature entails the highest risk of recurrent vascular events, explained first author Prof. Pierre Amarenco (Paris University, France) [2]. Ticagrelor monotherapy was not superior to aspirin in the SOCRATES trial [3]. However, in the subgroup of patients with ipsilateral atherosclerotic stenosis, ticagrelor was superior to aspirin [4].

The THALES trial (NCT03354429) randomised 11,016 patients to ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice dai...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on